Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
What If You Bought TEVA Earlier?
Estimate based on split history only. Excludes dividends, fees, taxes, and intraday movement.
Stock Split History
Newest split first. Cumulative multiple = compounded growth from that date to today.
| Split Date | Price Before | Ratio | Split Multiple | Cumulative |
|---|---|---|---|---|
| Jul 1, 2004 | $33.59 | 2-for-1 | 2× | 16× |
| Dec 6, 2002 | $19.31 | 2-for-1 | 2× | 8× |
| Feb 23, 2000 | $9.59 | 2-for-1 | 2× | 4× |
| Apr 14, 1993 | — | 2-for-1 | 2× | 2× |
Teva Pharmaceutical Industries Market Cap Timeline
Validated annual market-cap history is available from 1996. Split markers cover all 4 recorded splits. Filled dots have market-cap data for that year; hollow dots mark split years outside market-cap source coverage.